Colorectal Cancer Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Colorectal Cancer Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Summary

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical stage pipeline products, with a launch date assessment by market for colorectal cancer (CRC). In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional 7 geographical markets (7M), totaling 15 major markets (15MM). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

The report also analyzes the clinical and commercial landscapes of CRC, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology.

Additionally, the report evaluates indication-specific unmet needs and competitive assessment, and identifies key future players in the cell therapy market.

Synopsis

• Cell and gene therapy (CGT) is not an established therapy area in CRC, but there is an active clinical pipeline.
• The gene therapy/oncolytic virus pipeline is generally unpromising. Oncolytic viruses (OVs) are being evaluated in combination with immune checkpoint inhibitors for microsatellite-instability high patients. Highly tolerable safety profiles have been reported; however, efficacy remains to be demonstrated.
• GlobalData’s patient-based forecast projects the CRC cell & gene therapy market across the 8MM to reach $1.2 billion in 2031, while across the 15MM, overall CRC market sales are projected to reach a peak of $23.9 billion.
• CGT agents should aim to provide long-term disease control in metastatic CRC (mCRC) to add the most clinical value.

Key Highlights

• Report deliverables include a PowerPoint report and Excel-based forecast model
• Forecast includes 8 countries
• Forecast covers 2021-2031
• Seven markets are extrapolated, obtaining a 15-market value for all CRC therapeutics

Scope

• This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy

OBTAIN CELL & GENE THERAPY SALES FORECASTS ACROSS MULTIPLE REGIONS

GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES

Our indication specific forecast models answer questions such as -

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in eac h market?
• What is the total market value projected for the forecast end, in 2031?